Drug Profile
Manfidokimab - Akeso Biopharma
Alternative Names: AK-120 - Akeso Biopharma; IL-4R monoclonal antibodyLatest Information Update: 26 Oct 2023
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Anti-inflammatories; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Discontinued Asthma; Eosinophilic oesophagitis
Most Recent Events
- 23 Oct 2023 Akeso plans a phase II trial for Atopic Dermatitis (Treatment-experienced) in China (SC) (NCT06092762)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Atopic-dermatitis(In the elderly, In adults) in New Zealand (SC)
- 23 Mar 2023 Discontinued - Phase-I/II for Eosinophilic oesophagitis in China (Parenteral) (Akeso Biopharma pipeline, March 2023)